摘要
目的：观察多西紫杉醇联合替吉奥与奥沙利铂联合替吉奥治疗晚期胃癌的疗效及毒副反应。方法收集2008年3月至2012年9月来我院接受一线化疗的晚期胃癌患者168例，其中72例接受DS方案（多西紫杉醇＋替吉奥组）治疗，96例接受SOX方案（奥沙利铂＋替吉奥组）治疗。多西紫杉醇＋替吉奥组：多西紫杉醇75 mg／m2 d1，21 d／周期；替吉奥40 mg／m2，2次／d d1?14，21 d／周期。奥沙利铂＋替吉奥组：奥沙利铂130 mg／m2 d1，21 d／周期；替吉奥40 mg／m2，2次／d d1?14，21 d／周期。根据实体瘤疗效评价标准（RECIST）1?0版评估客观肿瘤反应，分为完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）、疾病进展（PD），计算临床有效率；依照国家癌症研究所常见毒性标准（NCI?CTC）3?0版评估毒副反应。结果无进展生存期（ PFS）显示多西紫杉醇＋替吉奥组中位数为6?55个月（5?15～7?95个月）；奥沙利铂＋替吉奥组为5?73个月（5?03～6?41个月），两者比较差异无统计学意义（ P＝0?169）。临床近期有效率多西紫杉醇＋替吉奥组为41?70％，奥沙利铂＋替吉奥组为43?80％，两组比较差异无统计学意义（ P＞0?05）。多西紫杉醇＋替吉奥组和奥沙利铂＋替吉奥组不良反应：最常见的Ⅲ?Ⅳ级血液学毒性是血小板减少（19?4％与8?3％）、贫血（13?9％与12?5％）。最常见的Ⅲ?Ⅳ级非血液学毒性是恶心和呕吐（11?1％与8?3％）和神经毒性（5?6％与12?5％），两组比较差异均无统计学意义（P均＞0?05）。结论多西紫杉醇联合替吉奥或奥沙利铂联合替吉奥化疗方案治疗胃癌均有较好的疗效，未见明显的差异，在晚期胃癌患者耐受良好。
Objective To observe the efficacy and adverse reactions on Docetexal plus Gio versus Ox?aliplatin plus Giofor for treatment of patients with advanced gastric cancer?Methods One hundred and sixty?eight cases patients with the advanced gastric cancer who were treated the first?line chemotherapy in the People′s Liberation Army Navy Anqing Hospital from March 2008 to September 2012 were selected as study sub?jects?There were 72 cases patients were underwent DS treatment( Docetexal plus Gio) ,96 cases were underwent SOX treatment( Oxaliplatin plus Gio)?In the DS group,Docetaxel with dose of 75 mg/m2 for 1 times/d,Giowith does of 40 mg/m2 for 2 times/d,both with 21 days for a period?In the SOX group,Oxaliplatin with dose of 130 mg/m2 for 1 times/d,Gio with dose of 40 mg/m2 for 2 times/d,both with 21 days for a period?According to re?sponse evaluation criteria in solid tumors( RECIST) 1?0 version to evaluate objective tumor response,divided in?to complete remission(CR),partial response(PR),stable disease(SD),disease progression(PD),calculated the clinical effective rates,according to the national cancer institute common toxicity criteria( NCI?CTC) 3?0 ver?sion to evaluate the adverse reaction?Results Progression?free survival( PFS) showed that median of DS group was 6?55 months(5?15?7?95 months),of SOX group was 5?73 months(5?03?6?41 months),the difference was not statistically significant(P=0?169)?Recent clinical efficiency of DS group was 41?70%,of SOX group was 43?80%,the difference was not statistically significant( P>0?05)?Adverse reactions of DS group and SOX group with the most common grade Ⅲ?Ⅳ hematology toxicity were thrombocytopenia ( 19?4% vs?8?3%) , anemia ( 13?9% vs?12?5%) , with the most common grade Ⅲ?Ⅳ non hematologic toxicity were nausea and vomiting ( 11?1% vs?8?3%) ,and nerve toxicity ( 5?6% vs?12?5%) , the difference were not statistically significant ( P>0?05)?Conclusion Docetexal plus Gio or Oxaliplatin plus Gioforreatment of patients with advanced gastric cancer is effective,no obvi
出处
《中国综合临床》
2016年第12期-,共4页
Clinical Medicine of China
